Earnings results for Tenax Therapeutics (NASDAQ:TENX)
Tenax Therapeutics, Inc. is estimated to report earnings on 08/16/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.13. The reported EPS for the same quarter last year was $-0.23.
Tenax Therapeutics last posted its earnings results on May 19th, 2021. The specialty pharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by $1.43. Tenax Therapeutics has generated ($1.33) earnings per share over the last year (($2.65) diluted earnings per share). Earnings for Tenax Therapeutics are expected to grow in the coming year, from ($1.60) to ($0.09) per share. Tenax Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 16th, 2021 based off prior year’s report dates.
Analyst Opinion on Tenax Therapeutics (NASDAQ:TENX)
1 Wall Street analysts have issued ratings and price targets for Tenax Therapeutics in the last 12 months. Their average twelve-month price target is $5.00, predicting that the stock has a possible upside of 218.47%. The high price target for TENX is $5.00 and the low price target for TENX is $5.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”
Tenax Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $5.00, Tenax Therapeutics has a forecasted upside of 218.5% from its current price of $1.57. Tenax Therapeutics has received no research coverage in the past 90 days.
Dividend Strength: Tenax Therapeutics (NASDAQ:TENX)
Tenax Therapeutics does not currently pay a dividend. Tenax Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Tenax Therapeutics (NASDAQ:TENX)
In the past three months, Tenax Therapeutics insiders have not sold or bought any company stock. 29.69% of the stock of Tenax Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Only 25.35% of the stock of Tenax Therapeutics is held by institutions.
Earnings and Valuation of Tenax Therapeutics (NASDAQ:TENX
Earnings for Tenax Therapeutics are expected to grow in the coming year, from ($1.60) to ($0.09) per share. The P/E ratio of Tenax Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Tenax Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Tenax Therapeutics has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here